FUSE MEDICAL, INC. — Earnings

Most recent reported period: FY2023 (Q2) (filed for period ending 2023-06-30) · sourced from SEC EDGAR

Next earnings (estimated): Fri, September 29, 2023 — 942 days overdue (likely already filed but EDGAR cache cold). Anchored to latest quarter-end + 91 days. Analyst-confirmed dates land in a follow-up wave.

Recent · last 8 quarters Future · next 8 quarters

YoY = vs same quarter prior year (seasonality-adjusted)

Quarter end	Revenue	YoY	Net Income	YoY	Op. Margin
2023-06-30	$5M	↑+7.0%	$308K	↑+195.2%	7.4%
2023-03-31	$4M	↓-12.5%	$-228K	↑+52.1%	-4.2%
2022-12-31	$5M	↓-19.4%	$3M	—	—
2022-09-30	$5M	↑+6.7%	$-9K	↑+98.7%	1.0%
2022-06-30	$5M	↓-17.6%	$-323K	↓-277.8%	-1.1%
2022-03-31	$5M	↑+2.6%	$-476K	↓-5.1%	-9.6%
2021-12-31	$6M	↓-13.6%	—	—	—
2021-09-30	$4M	↓-25.9%	$-697K	↓-966.1%	-16.0%

Analyst consensus estimates (EPS / Revenue) and implied move from options will land in a follow-up wave. For now, YoY-vs-prior-year-quarter is the surprise proxy.

Last earnings · FY2023 (Q2)

Revenue

$5M

↑+7.0% +$329K YoY

Net Income

$308K

Earnings surprise · last 8 quarters

YoY % change · proxy for analyst surprise until estimates land

EPS history · last 10 fiscal years

diluted, GAAP, annual

Note: EPS reflects WEIGHTED-AVERAGE diluted shares for each fiscal year. Pre-stock- split values can blow up the early bars if SEC's XBRL data isn't split-adjusted — flagged as a known limitation; cumulative split-adjustment is a follow-up.